CSPG4 is overexpressed in many tumor samples, while its expression in normal tissue samples is substantially lower, which makes it a possible target for immunotherapy of several malignancies, including melanoma, triple-negative breast cancer, mesothelioma, and others (Wang et al., 2010; Ilieva et al., 2018; Wang et al., 2011; Geldres et al., 2014). Here, CSPG4 is linked to mesothelioma.